National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood draw for the laboratory assessment: Blood sampling for the biobank and, in addition, as sub-studies are planned on sub-groups of patients, additional blood samples are planned for the patients in these sub-studies.

Study summary

This is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with HBV/HDV co-infection.

Eligibility

Primary outcome measure(s)

• To study the natural or treated history of patients infected with HDV according to different management modalities. — At the end of the follow-up, december 2027
  This is a cohort in which many events will be studied. As the objectives are multiple, no primary endpoint has been defined.

Trial sites (38)

More ANRS, Emerging Infectious Diseases trials in France

Other trials for the same condition